Week January 9th, 2004 through January 15th, 2004 |
|
The New Year started off strong and continues to show an upward trend with over $588 million of venture capital invested in 45 U.S based companies during this reporting period. The average deal size was approximately $13.07 million. The amount of venture capital invested this period is up 13% over last weeks $520 million.
|
|
|
|
Geographically, California received more than 44% of the total venture capital invested this period. California was home to 18 venture backed companies and three of the nation's top five deals. Following California was Massachusetts, where 10 companies raised $169.57 million. The largest financing in California this period was by Peninsula Pharmaceuticals for $57.9 million. Peninsula Pharmaceuticals is a privately owned, specialty pharmaceutical company focused on licensing, developing and commercializing anti-infective products for the North American and European markets.
|
|
|
|
|
The Biotech sector raised the most venture capital this period with 43%. A total of 10 Biotech companies raised $251.28 million in venture financings. The largest financing in the Biotech sector was by Peninsula Pharmaceuticals.
|
|
|
|
|
Companies raising their Series B round of funding represented 35% of the total venture capital deployed this period. The largest Series B financing was by Threshold Pharmaceuticals for a total of $41 million. Threshold Pharmaceuticals is a pharmaceutical company focused on the development of multiple cancer drugs targeting the unique metabolic properties of tumors.
|
|
|
|
|
|
The five largest venture deals this period are as follows:
|
|
|
Company |
Location |
Sector |
Investment |
|
1 |
Pennisula Pharmaceuticals, Inc. |
Alameda, CA |
Biotech |
$57.9 million |
|
2 |
Synta Pharmaceuticals Corp. |
Lexington, MA |
Biotech |
$50 million |
|
3 |
Threshold Pharmaceuticals |
San Francisco, CA |
Biotech |
$41 million |
|
4 |
Egenera, Inc. |
Marlboro, MA |
Software |
$30 million |
|
5 |
TargeGen, Inc. |
San Diego, CA |
Biotech |
$30 million |
|
|
|
|
The following thirty one investors funded the above mentioned top five venture capital investments in excess of $208 million:
|
|
1
|
Apax Partners |
|
1
|
A.M. Pappas & Associates |
|
2
|
AIG SunAmerica |
|
3
|
Austin Ventures |
|
4
|
Canaan Partners |
|
5
|
Caxton Group |
|
6
|
CDP Capital Technology Ventures |
|
7
|
China Development Industrial Bank |
|
8
|
CHL Medical Partners LP |
|
9
|
CSFB Private Equity |
|
10
|
Domain Associates, L.L.C. |
|
11
|
Duquesne Capital |
|
12
|
Enterprise Partners |
|
13
|
Forward Ventures |
|
14
|
Galleon Group |
|
15
|
Goldman Sachs |
|
16
|
Gollust Management |
|
17
|
Kodiak Venture Partners |
|
18
|
Lehman Brothers |
|
19
|
Montreux Equity Partners |
|
20
|
Morgenthaler Ventures |
|
21
|
Mountain Trail Investments |
|
22
|
OrbiMed Advisors LLC |
|
23
|
Pequot Ventures |
|
24
|
ProQuest Investments |
|
25
|
Shionogi and Co Inc |
|
26
|
Sofinnova Ventures, Inc. |
|
27
|
Spectrum Equity Investors |
|
28
|
Sutter Hill Ventures SHV |
|
29
|
Technology Crossover Ventures |
|
30
|
Three Arch Partners |
|
31
|
William Blair Capital Partners LLC |
|
|
|
|
Below you will find a breakdown for this reporting period of equity financings in the United States, Canada, and internationally:
|
|
INVESTMENTS WEEK OF January 9th
|
| |
$ |
# |
| |
Millions |
Deals |
| Equity - NYSE (1 IPO's) |
400 |
1 |
| Equity - NASDAQ |
18.7 |
5 |
| Equity - AMEX |
0 |
0 |
| Equity - OTC |
30.1 |
4 |
| Equity - Canadian Exchanges |
6 |
1 |
| Venture Capital - Canada |
11 |
2 |
| Venture Capital - Int'l |
41.77 |
8 |
|
NOTE: All the "equity" investments highlighted in the above table are non venture capital investments such as PIPE's or public offerings. With your paid subscription to Capital Hunter you can obtain immediate access to a complete detailed listing of this reporting period's 80 newly funded companies. As a paid customer you can also use our easy to use tools to mine our database with over 30,000 historic equity financings. We can also provide XML data feeds to our premium customers.
The Ultimate Goal of Capital Hunter's FUNDING WATCH newsletter is to provide our readers with a valuable, current and accurate source of information about the capital markets. WE WELCOME ANY AND ALL FEEDBACK ON HOW WE CAN MAKE THIS NEWSLETTER AND OUR SERVICE MORE USEFUL FOR YOU.
To be REMOVED from this free service, CLICK HERE |
|
|
|
©2003 Capital Hunter, Inc. all rights reserved
|
